

CLAIMS AS AMENDED 5/8/03

What is claimed is:

1. (Amended) An antibody which binds to a mammalian CC-chemokine receptor 2, wherein the antibody inhibits binding of a ligand to the receptor.
2. (Amended) An antibody according to Claim 1, wherein the antibody inhibits one or more functions associated with binding of the ligand to the receptor.
3. (Amended) An antibody according to Claim 1, wherein the mammalian CC-chemokine receptor 2 is a human CC-chemokine receptor 2.
4. (Amended) An antibody according to Claim 1, wherein the ligand is a chemokine.
5. (Amended) An antibody according to Claim 4, wherein the chemokine is selected from the group consisting of MCP-1, MCP-2, MCP-3, MCP-4 and combinations thereof.
6. (Amended) An antibody according to Claim 1, wherein the antibody is a monoclonal antibody.
7. (Amended) An antibody according to Claim 1, wherein the antibody is a human antibody.
9. (Amended) An antibody according to Claim 1, wherein the antibody is a humanized antibody.

current claims for U.S. Patent Application No. 09/898,513

10. (Amended) An antibody according to Claim 1, wherein the antibody is a recombinant antibody.
37. (Amended) A composition comprising an antibody which binds to a mammalian CC-chemokine receptor 2, wherein the antibody inhibits binding of a ligand to the receptor, and an optional physiologically acceptable vehicle.
38. (Amended) An antibody which binds to a mammalian CC-chemokine receptor 2, wherein the antibody inhibits binding of a ligand to the receptor with an IC_{50} of less than about 1.0 $\mu\text{g/ml}$.
39. (Amended) An antibody according to Claim 38 wherein the IC_{50} is less than about 0.05 $\mu\text{g/ml}$.
40. (Amended) An antibody which binds to a mammalian CC-chemokine receptor 2, wherein the antibody inhibits binding of a ligand to the receptor, and wherein the antibody binds the receptor with an affinity of at least about $0.1 \times 10^{-9} \text{ M}$.
41. (Amended) An antibody according to Claim 40, wherein the affinity is at least about $1 \times 10^{-9} \text{ M}$.
42. (Amended) An antibody according to Claim 40, wherein the affinity is at least about $3 \times 10^{-9} \text{ M}$.
43. (Amended) A method of treating a CC-chemokine receptor 2-mediated disorder in a patient, comprising administering to the patient an effective amount of an antibody which binds to a mammalian CC-chemokine receptor 2, wherein the antibody inhibits binding of a ligand to the receptor.
44. (New) An antigen-binding fragment of an antibody which binds to a mammalian

CC-chemokine receptor 2 and inhibits binding of a ligand to the receptor, wherein the antigen-binding fragment inhibits binding of a ligand to the receptor.

45. (New) An antigen-binding fragment according to Claim 44, wherein the antigen-binding fragment inhibits one or more functions associated with binding of the ligand to the receptor.
46. (New) An antigen-binding fragment according to Claim 44, wherein the mammalian CC-chemokine receptor 2 is a human CC-chemokine receptor 2.
47. (New) An antigen-binding fragment according to Claim 44, wherein the ligand is a chemokine.
48. (New) An antigen-binding fragment according to Claim 47, wherein the chemokine is selected from the group consisting of MCP-1, MCP-2, MCP-3, MCP-4 and combinations thereof.
49. (New) An antigen-binding fragment according to Claim 44, wherein the antibody is a monoclonal antibody.
50. (New) An antigen-binding fragment according to Claim 44, wherein the antibody is a human antibody.
51. (New) An antigen-binding fragment according to Claim 44, wherein the antigen-binding fragment is selected from the group consisting of an Fv fragment, an Fab fragment, an Fab' fragment and an F(ab')₂ fragment.
52. (New) An antigen-binding fragment according to Claim 44, wherein the antibody is a humanized antibody.

53. (New) An antigen-binding fragment according to Claim 44, wherein the antibody is a recombinant antibody.
54. (New) A composition comprising an antigen-binding fragment of an antibody which binds to a mammalian CC-chemokine receptor 2 and inhibits binding of a ligand to the receptor, wherein the antigen-binding fragment inhibits binding of a ligand to the receptor, and an optional physiologically acceptable vehicle.
55. (New) An antigen-binding fragment of an antibody which binds to a mammalian CC-chemokine receptor 2 and inhibits binding of a ligand to the receptor with an IC_{50} of less than about $1.0 \mu\text{g/ml}$, wherein the antigen-binding fragment inhibits binding of a ligand to the receptor with an IC_{50} of less than about $1.0 \mu\text{g/ml}$.
56. (New) An antigen-binding fragment of an antibody which binds to a mammalian CC-chemokine receptor 2 with an affinity of at least about $0.1 \times 10^{-9} \text{ M}$ and inhibits binding of a ligand to the receptor, wherein the antigen-binding fragment binds to a mammalian CC-chemokine receptor 2 with an affinity of at least about $0.1 \times 10^{-9} \text{ M}$ and inhibits binding of a ligand to the receptor.
57. (New) A method of treating a CC-chemokine receptor 2-mediated disorder in a patient, comprising administering to the patient an effective amount of an antigen-binding fragment of an antibody which binds to a mammalian CC-chemokine receptor 2 and inhibits binding of a ligand to the receptor, wherein the antigen-binding fragment inhibits binding of a ligand to the receptor.